Increased amputation risk with canagliflozin treatment: behind the large cardiovascular benefit?

A growing body of evidence suggests that sodium-glucose cotransporter 2 (SGLT2) inhibitors appear to be a powerful option to improve the cardiovascular (CV) prognosis in high CV-risk patients with type 2 diabetes. Despite a significant reduction in major adverse CV events with SGLT2 inhibitor treatm...

Descripción completa

Detalles Bibliográficos
Autores principales: Tanaka, Atsushi, Node, Koichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5639481/
https://www.ncbi.nlm.nih.gov/pubmed/29025400
http://dx.doi.org/10.1186/s12933-017-0611-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5639481/
https://www.ncbi.nlm.nih.gov/pubmed/29025400
http://dx.doi.org/10.1186/s12933-017-0611-x

Ejemplares similares